Roche

Roche

The frontrunner in personalised healthcare

Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas.
Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.

Our strategy

We focus on finding new medicines and diagnostics and establishing data-based insights that evolve the practice of medicine and help patients live longer, better lives.
Healthcare is undergoing tremendous changes but our vision is clear. We are doing now what patients need next. From developing diagnostics and treatments, to harnessing the power of data to shape innovations of the future, we are an integrated healthcare company with a culture of integrity, courage and passion. 
For over 125 years, we’ve been developing diagnostics and medicines for a wide range of chronic and life threatening health conditions that continue to revolutionise healthcare. Being a family-owned company allows us to focus on long-lasting investments, take greater risks and explore innovative new ways to improve people’s health around the world. 
As a global leader in healthcare, we are one of the world’s largest biotech companies and the leading supplier of in-vitro diagnostics. We’re an innovator across major disease areas, including oncology, neurology, infectious diseases, and ophthalmology. We’ve partnered with many forward-thinking, entrepreneurial and groundbreaking organisations that have one thing in common - the belief that cutting-edge science and technology can and will improve human health.

Cardiometabolic diseases

Cardiometabolic diseases are one of the greatest challenges we face. Our focus lies in countering the threat through innovative diagnostic and preventive solutions.

Challenge

Cardiometabolic disease is the number one cause of mortality, accounting for 31% of all global deaths—75% of which occur in low- and middle-income countries.
Cardiometabolic disease is not a single ailment, but rather a spectrum of conditions.1 Early intervention is crucial to prevent complications. Most cardiovascular diseases can be prevented by addressing certain risk factors, such as tobacco use, unhealthy diet and obesity, physical inactivity, and harmful use of alcohol. However, the reality of many situations is that early warning signs are ignored and diagnostic solutions are required to inform appropriate intervention.

Focus

We are focused on bringing better diagnostics solutions to support early intervention and improve outcomes.
Today, advanced technologies and our evolved understanding of disease present new opportunities to personalise treatment, reduce unnecessary costs, and protect people in their time of need. The use of tests to assess risk, screen, diagnose, predict, and monitor cardiac disease have been essential tools in protecting patients, helping to reduce anxiety, avoid overcrowding of the emergency department, and help save lives.

References:

• American College for Cardiology. Cardiometabolic Initiatives. https://www.acc.org/tools-and-practice-support/quality-programs/cardiometabolic-health-alliance. Accessed March 9, 2021.

Source: https://www.roche.com/